{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T09:07:11Z","timestamp":1762160831709,"version":"build-2065373602"},"reference-count":49,"publisher":"Wiley","issue":"13","license":[{"start":{"date-parts":[[2010,8,18]],"date-time":"2010-08-18T00:00:00Z","timestamp":1282089600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Movement Disorders"],"published-print":{"date-parts":[[2010,10,15]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Long\u2010acting full dopamine D<jats:sub>2<\/jats:sub> agonists produce less dyskinesia in 1\u2010methyl\u20104\u2010phenyl\u20101,2,3,6\u2010tetrahydropyridine (MPTP)\u2010treated primates and in Parkinson's disease than effective antiparkinsonian doses of levodopa. They do not however, prevent priming for dyskinesia expression on subsequent levodopa exposure. In contrast, the effects of partial D<jats:sub>2<\/jats:sub> receptor agonists on dyskinesia are unclear. We now examine the ability of the partial D<jats:sub>2<\/jats:sub> agonist pardoprunox (SLV308) to improve motor function and its propensity to prime for dyskinesia in drug na\u00efve, MPTP\u2010treated common marmosets. Previously, drug na\u00efve, MPTP\u2010treated common marmosets were treated with equivalent doses of either pardoprunox (SLV308) (0.1 mg\/kg po), ropinirole (0.18 mg\/kg po), or levodopa (10 mg\/kg po BID) for 28 days. All treatments induced a similar reduction of motor disability. Dyskinesia induced by levodopa was of greater intensity than that following administration of either pardoprunox (SLV308) or ropinirole. Administration of pardoprunox (SLV308) resulted in dyskinesia that was less intense and of shorter duration than either ropinirole or levodopa. At the end of drug treatment, acute challenge with levodopa resulted in the expression of marked dyskinesia in animals that had previously received chronic levodopa or ropinirole treatment. However, animals previously treated with pardoprunox (SLV308) showed only mild dyskinesia in response to the levodopa challenge. These results suggest that the partial D<jats:sub>2<\/jats:sub> agonist pardoprunox (SLV308) is less likely to prime for dyskinesia or to lead to the expression of dyskinesia than either levodopa or full dopamine agonists. \u00a9 2010 Movement Disorder Society<\/jats:p>","DOI":"10.1002\/mds.23249","type":"journal-article","created":{"date-parts":[[2010,8,18]],"date-time":"2010-08-18T23:01:19Z","timestamp":1282172479000},"page":"2059-2066","source":"Crossref","is-referenced-by-count":16,"title":["Pardoprunox reverses motor deficits but induces only mild dyskinesia in MPTP\u2010treated common marmosets"],"prefix":"10.1002","volume":"25","author":[{"given":"Louisa Clare","family":"Johnston","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael John","family":"Jackson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah","family":"Rose","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew Christopher","family":"McCreary","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Jenner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2010,8,18]]},"reference":[{"key":"e_1_2_1_6_1_2_2","first-page":"339","article-title":"Variations in the \u201con\u2010off\u201d phenomenon","volume":"5","author":"Duvoisin RC","year":"1974","journal-title":"Adv Neurol"},{"key":"e_1_2_1_6_1_3_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.40.2.340"},{"issue":"1","key":"e_1_2_1_6_1_4_2","first-page":"S160","article-title":"Clinical pharmacology of levodopa induced dyskinesia","volume":"47","author":"Nutt JG","year":"2000","journal-title":"Ann Neurol"},{"issue":"1","key":"e_1_2_1_6_1_5_2","first-page":"S179","article-title":"Medical treatment of levodopa\u2010induced dyskinesias","volume":"47","author":"Rascol O","year":"2000","journal-title":"Ann Neurol"},{"issue":"2","key":"e_1_2_1_6_1_6_2","first-page":"11\/52","article-title":"The pharmacological therapeutic management of levodopa\u2010induced dyskinesias in patients with Parkinson's disease","volume":"247","author":"Rascol O","year":"2000","journal-title":"J Neurol"},{"key":"e_1_2_1_6_1_7_2","doi-asserted-by":"publisher","DOI":"10.1002\/mds.20459"},{"key":"e_1_2_1_6_1_8_2","doi-asserted-by":"publisher","DOI":"10.1038\/ncpneuro0222"},{"key":"e_1_2_1_6_1_9_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002826-199704000-00001"},{"key":"e_1_2_1_6_1_10_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200005183422004"},{"key":"e_1_2_1_6_1_11_2","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1001\/jama.284.15.1931","article-title":"Pramipexole versus levodopa as initial treatment for PD","volume":"28","author":"Parkinson's Study Group","year":"2000","journal-title":"JAMA"},{"key":"e_1_2_1_6_1_12_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.35.8.1196"},{"key":"e_1_2_1_6_1_13_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.37.5.826"},{"key":"e_1_2_1_6_1_14_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-199855001-00004"},{"issue":"6","key":"e_1_2_1_6_1_15_2","first-page":"13","article-title":"Ropinirole: current staus of the studies","volume":"251","author":"Jost W","year":"2004","journal-title":"J Neurol"},{"key":"e_1_2_1_6_1_16_2","doi-asserted-by":"publisher","DOI":"10.1002\/mds.20988"},{"key":"e_1_2_1_6_1_17_2","doi-asserted-by":"publisher","DOI":"10.1002\/mds.21743"},{"key":"e_1_2_1_6_1_18_2","doi-asserted-by":"publisher","DOI":"10.1002\/mds.20324"},{"key":"e_1_2_1_6_1_19_2","doi-asserted-by":"publisher","DOI":"10.1002\/mds.21292"},{"key":"e_1_2_1_6_1_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/0006-8993(86)90783-3"},{"key":"e_1_2_1_6_1_21_2","doi-asserted-by":"publisher","DOI":"10.1002\/mds.870100606"},{"key":"e_1_2_1_6_1_22_2","doi-asserted-by":"publisher","DOI":"10.1002\/mds.870130207"},{"key":"e_1_2_1_6_1_23_2","doi-asserted-by":"publisher","DOI":"10.1002\/mds.1149"},{"key":"e_1_2_1_6_1_24_2","doi-asserted-by":"publisher","DOI":"10.1002\/mds.20276"},{"key":"e_1_2_1_6_1_25_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.WNF.0000220818.71231.DF"},{"key":"e_1_2_1_6_1_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.expneurol.2006.10.005"},{"issue":"1","key":"e_1_2_1_6_1_27_2","first-page":"950","article-title":"Treatment of Parkinson's disease with a dopamine partial agonist","volume":"7","author":"Corsini G","year":"1984","journal-title":"Clin Neuropharmacol"},{"key":"e_1_2_1_6_1_28_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF01245972"},{"key":"e_1_2_1_6_1_29_2","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1097\/00002826-198702000-00005","article-title":"Transdihydrolisuride in Parkinsonism","volume":"10","author":"Critchley P","year":"1987","journal-title":"Clin Neuropharmacol"},{"key":"e_1_2_1_6_1_30_2","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1007\/BF02335941","article-title":"Terguride in the treatment of Parkinson's disease: preliminary experience","volume":"11","author":"Giovannini P","year":"1990","journal-title":"Ital J Neurol Sci"},{"key":"e_1_2_1_6_1_31_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002826-199110000-00010"},{"key":"e_1_2_1_6_1_32_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002826-199312000-00008"},{"key":"e_1_2_1_6_1_33_2","doi-asserted-by":"publisher","DOI":"10.1002\/mds.870080214"},{"key":"e_1_2_1_6_1_34_2","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/S0022-3565(25)20396-2","article-title":"Effect of D1 and D2 agonists and antagonists on dyskinesia produced by L\u2010dopa in 1\u2010methyl\u20104\u2010phenyl\u20101,2,3,6\u2010tetrahydropyridine\u2010treated monkeys","volume":"259","author":"Gomez\u2010Mancilla B","year":"1991","journal-title":"J Pharmacol Exp Ther"},{"key":"e_1_2_1_6_1_35_2","doi-asserted-by":"publisher","DOI":"10.1002\/ana.410330515"},{"key":"e_1_2_1_6_1_36_2","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/S0022-3565(25)09546-1","article-title":"Combination treatment of the partial D2 agonist terguride with the D1 agonist SKF 82958 in 1\u2010methyl\u20104\u2010phenyl\u20101,2,3,6\u2010tetrahydropyridine\u2010lesioned parkinsonian cynomolgus monkeys","volume":"273","author":"Akai T","year":"1995","journal-title":"J Pharmacol Exp Ther"},{"key":"e_1_2_1_6_1_37_2","doi-asserted-by":"publisher","DOI":"10.1002\/syn.20330"},{"key":"e_1_2_1_6_1_38_2","first-page":"134P","article-title":"The novel dopamine D2 receptor partial agonist PARDOPRUNOX (SLV308) reverses motor disability in MPTP\u2010lesioned common marmosets","author":"Johnston LC","year":"2001","journal-title":"Br J Pharmacol"},{"key":"e_1_2_1_6_1_39_2","first-page":"220.3","article-title":"PARDOPRUNOX (SLV308): Antiparkinsonian effects in the MPTP\u2010treated common marmosets (Callithrix jacchus)","volume":"27","author":"Johnston LC","year":"2001","journal-title":"Soc Neurosci Asbtr"},{"issue":"1","key":"e_1_2_1_6_1_40_2","first-page":"P2158","article-title":"Association between intrinsic activity and the antiparkinsonian effects of a novel D2 agonist series in the MPTP\u2010treated primate model of PD","volume":"10","author":"Johnston LC","year":"2003","journal-title":"Eur J Neurol"},{"key":"e_1_2_1_6_1_41_2","doi-asserted-by":"publisher","DOI":"10.1002\/mds.870120616"},{"key":"e_1_2_1_6_1_42_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF02244422"},{"key":"e_1_2_1_6_1_43_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.42.6.1241"},{"key":"e_1_2_1_6_1_44_2","doi-asserted-by":"publisher","DOI":"10.1002\/mds.870090512"},{"key":"e_1_2_1_6_1_45_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.61.6_suppl_3.S4"},{"key":"e_1_2_1_6_1_46_2","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/35072550","article-title":"Experimental Models of Parkinson's Disease","volume":"2","author":"Flint Beal M","year":"2001","journal-title":"Nat Rev Neurosci"},{"key":"e_1_2_1_6_1_47_2","first-page":"P359","article-title":"A study in dopamine D2 receptor occupancy after multipleoral administration of SLV308 to healty male volunteers by means of positron emission tomography using 11C\u2010raclopride","volume":"17","author":"De Vries MH","year":"2003","journal-title":"Mov Disord"},{"key":"e_1_2_1_6_1_48_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00702-007-0727-3"},{"key":"e_1_2_1_6_1_49_2","doi-asserted-by":"publisher","DOI":"10.1002\/mds.22022"},{"issue":"3","key":"e_1_2_1_6_1_50_2","first-page":"103","article-title":"Pardoprunox (SLV308) in patients with early stage Parkinson's disease\u2014a phase II, double\u2010blind, placebo\u2010controlled, international, multi\u2010centre study by the Bruegel Study Group","volume":"15","author":"Bronzova J","year":"2008","journal-title":"Eur J Neurol"}],"container-title":["Movement Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fmds.23249","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/movementdisorders.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/mds.23249","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T10:53:36Z","timestamp":1760957616000},"score":1,"resource":{"primary":{"URL":"https:\/\/movementdisorders.onlinelibrary.wiley.com\/doi\/10.1002\/mds.23249"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,8,18]]},"references-count":49,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2010,10,15]]}},"alternative-id":["10.1002\/mds.23249"],"URL":"https:\/\/doi.org\/10.1002\/mds.23249","archive":["Portico"],"relation":{},"ISSN":["0885-3185","1531-8257"],"issn-type":[{"type":"print","value":"0885-3185"},{"type":"electronic","value":"1531-8257"}],"subject":[],"published":{"date-parts":[[2010,8,18]]}}}